CD38在皮肤T细胞淋巴瘤病理生物学中的作用及联合治疗干预的潜力
研究显示皮肤T细胞淋巴瘤(CTCL)患者样本及衍生细胞系表达CD38,αCD38抗体在小鼠模型中可有效靶向CD38,但残留肿瘤细胞CD38表达丢失;CRISPR-Cas9敲除CD38后细胞致癌基因表达升高、迁移减少、NAD+升高、呼吸增强,体内移植肿瘤更具侵袭性;组蛋白去乙酰化酶抑制剂帕比司他剂量依赖性增加CTCL细胞表面CD38表达,与αCD38抗体联用较单用抗体显著改善小鼠生存。
要点
- CTCL患者样本及衍生细胞系表达CD38,αCD38抗体在小鼠模型中可靶向CD38。
- αCD38抗体治疗后残留肿瘤细胞CD38表达丢失。
- 帕比司他剂量依赖性增加CTCL细胞表面CD38表达,与αCD38抗体联用较单用抗体显著改善小鼠生存。
核心结论
- CD38在CTCL细胞中表达并可作为αCD38抗体的靶点。
- αCD38抗体治疗导致CTCL细胞显著减少,而残留细胞CD38表达丢失。
- 帕比司他与αCD38抗体双联合治疗在小鼠CTCL模型中较单用αCD38抗体改善生存结局。
研究设计与样本
- 研究使用患者样本及衍生CTCL细胞系,并采用小鼠模型进行体内外实验。
- 使用CRISPR-Cas9构建CD38缺陷(CD38KO)CTCL细胞。
- 在小鼠模型中进行αCD38抗体治疗及CD38KO细胞移植实验。
- 在小鼠CTCL模型中比较帕比司他联合αCD38抗体与单用αCD38抗体的生存结局。
主要发现
- 患者样本和衍生细胞系在CTCL细胞上表达CD38,αCD38抗体在小鼠模型中有效靶向CD38。
- 体内αCD38抗体治疗导致残留肿瘤细胞CD38表达丢失。
- CD38KO CTCL细胞显示致癌基因B-catenin、TCF7和BCL6表达升高,同时迁移减少。
- CD38KO细胞中NAD+水平升高,在CD38WT细胞中CD38抑制后细胞呼吸增加。
- 体内CD38KO细胞移植导致更具侵袭性的肿瘤,可能由于β-catenin、Bcl6和Tcf-1信号升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cutaneous T-Cell Lymphoma (CTCL) is a non-Hodgkin's lymphoma involving malignant skin-homing T-cells, characterized by variable severity and limited treatment options. Our study shows that patient samples and derived cell lines express CD38 on CTCL cells, and αCD38 antibodies effectively target CD38 in a mouse model. In vivo αCD38 antibody treatment led to the loss of CD38 expression in residual tumor cells, highlighting the need for innovative strategies to improve CTCL outcomes despite the CD38 loss in residual tumor cells. To investigate the role of CD38 in CTCL pathology, we used CRISPR-Cas9 to create CD38-deficient (CD38KO) CTCL cells. These CD38KO cells showed higher expression of oncogenes B-catenin, TCF7, and BCL6, along with reduced migration. Elevated NAD+ levels in CD38KO cells increased cellular respiration after CD38 inhibition in CD38WT cells. In vivo, CD38KO cell transplants led to more aggressive tumors, likely due to elevated β-catenin, Bcl6, and Tcf-1 signaling. Prior research in multiple myeloma showed αCD38 antibody efficacy relies on CD38 expression. We discovered that panobinostat, a histone deacetylase inhibitor, increased surface CD38 expression in CTCL cells dose-dependently. Combining panobinostat with αCD38 antibody in a CTCL mouse model significantly improved survival compared to the antibody alone, underscoring CD38's therapeutic potential in CTCL. CD38 is expressed in CTCL cells and can be targeted with αCD38 antibody. αCD38 antibody treatment leads to a significant reduction in CTCL cells, while residual cells lose CD38 expression. Knocking out CD38 from CTCL cells leads to increases in intracellular NAD+ and increased cellular respiration. Additionally, CD38KO cells have increased protein levels of β-catenin, Tcf1 (encoded by TCF7), and Bcl6. CD38KO CTCL cells grow more aggressively in vivo than CD38WT CTCL cells. Treating CTCL cells with panobinostat increases CD38 expression. A dual combination treatment of panobinostat and αCD38 antibody in a mouse model of CTCL improved survival outcomes compared to αCD38 antibody treatment alone. (Figure made with Biorender.com).
引用
- Isabelle C, Boles A, McConnell K, et al. CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention. Leukemia. 2025. PMID: 40057636. doi:10.1038/s41375-025-02551-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。